These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. MAGE-A3: an immunogenic target used in clinical practice. Esfandiary A; Ghafouri-Fard S Immunotherapy; 2015; 7(6):683-704. PubMed ID: 26100270 [TBL] [Abstract][Full Text] [Related]
5. [NY-ESO-1 and cancer immunotherapy]. Peng JR; Leng XS Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):371-7. PubMed ID: 18795604 [TBL] [Abstract][Full Text] [Related]
6. DNA vaccine for cancer immunotherapy. Yang B; Jeang J; Yang A; Wu TC; Hung CF Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927 [TBL] [Abstract][Full Text] [Related]
7. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers. Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913 [TBL] [Abstract][Full Text] [Related]
8. Tumor vaccine: current trends in antigen specific immunotherapy. Baral R Indian J Exp Biol; 2005 May; 43(5):389-406. PubMed ID: 15900903 [TBL] [Abstract][Full Text] [Related]
9. Cancer vaccines and immunotherapies: emerging perspectives. Henderson RA; Mossman S; Nairn N; Cheever MA Vaccine; 2005 Mar; 23(17-18):2359-62. PubMed ID: 15755628 [TBL] [Abstract][Full Text] [Related]
10. Tumor antigens as surrogate markers and targets for therapy and vaccines. Dalgleish A; Pandha H Adv Cancer Res; 2007; 96():175-90. PubMed ID: 17161680 [TBL] [Abstract][Full Text] [Related]
11. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy. Seremet T; Brasseur F; Coulie PG Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282 [TBL] [Abstract][Full Text] [Related]
12. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Bodey B; Bodey B; Siegel SE; Kaiser HE Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341 [TBL] [Abstract][Full Text] [Related]
13. Cancer vaccines: an update with special focus on ganglioside antigens. Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591 [TBL] [Abstract][Full Text] [Related]
14. [Epitope peptide vaccine with oncoantigen for cancer and its biomarker]. Hazama S; Maeda K; Oka M Nihon Rinsho; 2012 Dec; 70(12):2189-93. PubMed ID: 23259395 [TBL] [Abstract][Full Text] [Related]
16. Cancer vaccines: what do we need to measure in clinical trials? Kudrin A Hum Vaccin Immunother; 2014; 10(11):3236-40. PubMed ID: 25483508 [TBL] [Abstract][Full Text] [Related]